400 related articles for article (PubMed ID: 24475168)
1. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis.
Lv R; Qiao W; Wu Z; Wang Y; Dai S; Liu Q; Zheng X
PLoS One; 2014; 9(1):e86692. PubMed ID: 24475168
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Lawson MM; Thomas AG; Akobeng AK
Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
[TBL] [Abstract][Full Text] [Related]
3. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.
Thukral C; Cheifetz A; Peppercorn MA
Drugs; 2006; 66(16):2059-65. PubMed ID: 17112300
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis.
Huang X; Lv B; Jin HF; Zhang S
Eur J Clin Pharmacol; 2011 Aug; 67(8):759-66. PubMed ID: 21691804
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.
Lopez A; Ford AC; Colombel JF; Reinisch W; Sandborn WJ; Peyrin-Biroulet L
Dig Liver Dis; 2015 May; 47(5):356-64. PubMed ID: 25661014
[TBL] [Abstract][Full Text] [Related]
8. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine A for induction of remission in severe ulcerative colitis.
Shibolet O; Regushevskaya E; Brezis M; Soares-Weiser K
Cochrane Database Syst Rev; 2005 Jan; (1):CD004277. PubMed ID: 15674937
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.
Thorlund K; Druyts E; Mills EJ; Fedorak RN; Marshall JK
J Crohns Colitis; 2014 Jul; 8(7):571-81. PubMed ID: 24491514
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.
Kohn A; Prantera C; Pera A; Cosintino R; Sostegni R; Daperno M
Dig Liver Dis; 2002 Sep; 34(9):626-30. PubMed ID: 12405248
[TBL] [Abstract][Full Text] [Related]
12. Infliximab clinically treating ulcerative colitis: A systematic review and meta-analysis.
Guo C; Wu K; Liang X; Liang Y; Li R
Pharmacol Res; 2019 Oct; 148():104455. PubMed ID: 31562896
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
Su C; Salzberg BA; Lewis JD; Deren JJ; Kornbluth A; Katzka DA; Stein RB; Adler DR; Lichtenstein GR
Am J Gastroenterol; 2002 Oct; 97(10):2577-84. PubMed ID: 12385442
[TBL] [Abstract][Full Text] [Related]
15. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review.
Filippi J; Allen PB; Hébuterne X; Peyrin-Biroulet L
Curr Drug Targets; 2011 Sep; 12(10):1440-7. PubMed ID: 21466486
[TBL] [Abstract][Full Text] [Related]
16. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
[TBL] [Abstract][Full Text] [Related]
17. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis.
Stidham RW; Lee TC; Higgins PD; Deshpande AR; Sussman DA; Singal AG; Elmunzer BJ; Saini SD; Vijan S; Waljee AK
Aliment Pharmacol Ther; 2014 Apr; 39(7):660-71. PubMed ID: 24506179
[TBL] [Abstract][Full Text] [Related]
18. Infliximab for patients with refractory ulcerative colitis.
Chey WY
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S30-3. PubMed ID: 11380041
[TBL] [Abstract][Full Text] [Related]
19. Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
Barberio B; Black CJ; Savarino EV; Ford AC
J Crohns Colitis; 2021 May; 15(5):733-741. PubMed ID: 33175102
[TBL] [Abstract][Full Text] [Related]
20. [The role of anti-TNF therapy in ulcerative colitis].
Cuković-Cavka S; Vucelić B; Urek MC; Brinar M; Turk N
Acta Med Croatica; 2013 Apr; 67(2):171-7. PubMed ID: 24471300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]